A phase I trial of IMP701 LAG03 antibody for the treatment of cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2018
At a glance
- Drugs IMP 701 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 29 Mar 2018 According to an Immutep Limited media release, GSK could extend the study to additional indications including rheumatoid arthritis and multiple sclerosis subjects to evidence of efficacy.
- 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
- 18 Aug 2015 New trial record